Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Published May 31, 2023
kelly and chris are amazing, i have been doing weight loss treatments with them and i am very happy with the results and how knowledgeable they are i highly recommend
Clin Sci (Lond) (1998) 95:3259.10.1042/CS19980051 46 BatterhamRLBloomSR
The retatrutide dose schedule tested in clinical settings follows a different escalation pattern than tirzepatide, with wider dose ranges and more complex titration options
Based on typical FDA review timelines and the current progress of trials, analysts project: Phase 3 trial completion: Late 2025 to early 2026 FDA submission: First half of 2026 Potential FDA approval: Q3 2026 to Q1 2027 Commercial availability: 2-3 months post-approval The FDA has not granted any special designations (Breakthrough Therapy, Fast Track) for Retatrutides obesity indication, which may mean standard review timelines apply
